Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma

Cancer

Volumn 98, Issue 6, 2003, Pages 1196-1205

  Wang, Eunice S ^a,b   Straus, David J ^a,b   Teruya Feldstein, Julie ^b   Qin, Jing ^a   Portlock, Carol ^a,b   Moskowitz, Craig ^a,b   Goy, Andre ^a,b   Hedrick, Eric ^a,b   Zelenetz, Andrew D ^a,b   Noy, Ariela ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Burkitt lymphoma; Human immunodeficiency virus; Intensive chemotherapy; Non Hodgkin lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INDINAVIR; LAMIVUDINE; METHOTREXATE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION COMPLICATION; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; TUMOR LYSIS SYNDROME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, AIDS-RELATED; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0042418171     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11628     Document Type: Article

References (38)

1. The Non-Hodgkin's Lymphoma Pathologic Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
3. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193-207.
4. Burkitt D. Long-term remissions following one and twodose chemotherapy for African lymphoma. Cancer. 1967;20:756-759.
5. Ostronoff M, Soussain C, Zambon E, et al. Burkitt's lymphoma in adults: a retrospective study of 46 cases. Nouv Rev Fr Hematol. 1992;34:389-397.
6. Straus DJ. Treatment of Burkitt's lymphoma in HIV-positive patients. Biomed Pharmacother. 1996;50:447-450.
7. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641-1648.
8. Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA. 1991;266:84-88.
9. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925-934.
10. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264-1274.
11. Carbone A, Gloghini A, Gaidano G, et al. AIDS-related Burkitt's lymphoma. Morphologic and immunophenotypic study of biopsy specimens. Am J Clin Pathol. 1995;103:561-567.
12. Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood. 1992;80:8-20.
13. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805-809.
14. Spina M, Tirelli U, Zagonel V, et al. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer. 1998;82:766-774.
15. Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol. 1998;16:3788-3795.
16. Gill PS, Levine AM, Krailo M, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol. 1987;5:1322-1328.
17. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
20. Rosner B. Hypothesis testing: categorical data. In: Rosner B. Fundamentals of biostatistics. Belmont, CA: Wadsworth Publishing Co., 1994:345-442.
21. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
22. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
23. Rodriguez V, Cabanillas F, Burgess MA, et al. Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. Blood. 1977;49:325-333.
24. Straus DJ, Wong GY, Liu J, et al. Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia. Am J Med. 1991;90:328-337.
25. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986;104:757-765.
26. O'Brien JP. An economic analysis of the NHL-15 protocol for diffuse aggressive lymphomas: the potential for substantially reducing cost by improving outcomes [abstract]. Am Soc Hematol. 1997;90:249a.
27. McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol. 1991;9:941-946.
28. Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986;4:847-858.
29. Longo DL, Duffey PL, Jaffe ES, et al. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a highgrade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol. 1994;12:2153-2159.
30. Ziegler JL. Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. N Engl J Med. 1977;297:75-80.
31. Lopez TM, Hagemeister FB, McLaughlin P, et al. Small noncleaved cell lymphoma in adults: superior results for Stages I-III disease. J Clin Oncol. 1990;8:615-622.
32. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171-2178.
33. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol. 2001;112:909-915.
34. Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med. 1993;95:188-196.
35. Oksenhendler E, Gerard L, Dubreuil ML, et al. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;39:87-95.
36. Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol. 1993;11:1099-1107.
37. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
38. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94:1492-1499.